Biocompatibility and toxicology effects of graphene oxide in cancer, normal, and primary immune cells.

Graphene oxide (GO) has received enormous attention regarding its possible applications in medical areas including cancer treatment. Nevertheless, graphene biocompatibility and its interactions with cancer, normal and immune system cells still remain a major issue. In the current study, we focused on the immunological impact of GO in the oxidative burst by GO produced in fresh isolated primary human neutrophils, the most abundant leukocyte of immune system. We also studied the GO cytotoxicity, cell uptake, and genotoxicity in fresh isolated primary human monocyte, neutrophil, human carcinoma cervical (HeLa) and L929 cells. GO biocompatibility was also analyzed in human red blood cell (hemocompatibility) and in primary human T lymphocytes (T cell). We observed that GO can interact with HeLa in vitro and immune system cells, but in major extension with cancer cells. The latter opened the way for further studies on the effects of GO on immune system pathways and treatments for human cancer at lower concentrations.